Wealth Advisory Solutions LLC trimmed its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 25.9% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 19,114 shares of the company's stock after selling 6,679 shares during the period. Wealth Advisory Solutions LLC's holdings in Zoetis were worth $3,147,000 at the end of the most recent quarter.
A number of other large investors also recently modified their holdings of the business. Rakuten Securities Inc. boosted its position in Zoetis by 5,533.3% during the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock valued at $28,000 after purchasing an additional 166 shares during the last quarter. Navigoe LLC acquired a new position in shares of Zoetis during the 4th quarter worth approximately $30,000. Cornerstone Planning Group LLC raised its stake in shares of Zoetis by 79.3% during the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock worth $30,000 after purchasing an additional 88 shares in the last quarter. Murphy & Mullick Capital Management Corp acquired a new stake in shares of Zoetis in the 4th quarter valued at approximately $44,000. Finally, Sound Income Strategies LLC boosted its holdings in shares of Zoetis by 141.4% in the 1st quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock valued at $46,000 after buying an additional 164 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.
Insiders Place Their Bets
In other Zoetis news, EVP Roxanne Lagano sold 652 shares of the company's stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total value of $110,840.00. Following the sale, the executive vice president owned 15,129 shares in the company, valued at approximately $2,571,930. The trade was a 4.13% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 0.18% of the stock is owned by insiders.
Analyst Ratings Changes
A number of brokerages have commented on ZTS. Stifel Nicolaus cut shares of Zoetis from a "buy" rating to a "hold" rating and cut their price target for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. UBS Group reduced their target price on Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research note on Wednesday, May 7th. Finally, Piper Sandler increased their price target on Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a research note on Monday, May 12th. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $212.13.
Read Our Latest Analysis on Zoetis
Zoetis Price Performance
NYSE:ZTS traded up $0.88 during trading hours on Thursday, hitting $159.15. The company's stock had a trading volume of 1,350,963 shares, compared to its average volume of 3,007,645. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.74 and a quick ratio of 1.04. The stock has a fifty day simple moving average of $161.30 and a 200-day simple moving average of $161.97. The company has a market capitalization of $70.85 billion, a P/E ratio of 28.61, a PEG ratio of 2.62 and a beta of 0.91.
Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 27.12% and a return on equity of 55.48%. The company had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.20 billion. During the same period last year, the company posted $1.38 EPS. The firm's quarterly revenue was up 1.4% compared to the same quarter last year. On average, analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.
Zoetis Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be paid a $0.50 dividend. The ex-dividend date of this dividend is Friday, July 18th. This represents a $2.00 annualized dividend and a dividend yield of 1.26%. Zoetis's dividend payout ratio is 35.91%.
Zoetis Profile
(
Free Report)
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
See Also

Before you consider Zoetis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list.
While Zoetis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.